GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

Shares of GSK PLC GSK inched up 0.59% to £13.64 Thursday, on what proved to be an all-around positive trading session for the ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

Bullish option flow detected in GSK (GSK) Pharma with 3,057 calls trading, 1.1x expected, and implied vol increasing over 4 points to 29.80%. Feb-25 34 calls and 1/31 weekly 34 calls are the most ...